NEW YORK (GenomeWeb) – Cell-and bead-based screening technologies firm IntelliCyt has closed a $2.5 million secured term loan agreement and a $1.5 million revolving line of credit from Oxford Finance, the financing firm announced today.

Albuquerque, NM-based IntelliCyt will use the debt facility for working capital, as well as product development and marketing. The company develops high-throughput, high-content screening products for phenotypic drug discovery, antibody discovery, and in vivo toxicity testing.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.